New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
07:37 EDTAEZSAeterna Zentaris announces first patient treated for Phase 2 trial with AEZS-108
Aeterna Zentaris announced that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the company's targeted doxorubicin peptide conjugate, AEZS-108.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:31 EDTAEZSAeterna Zentaris recruited 500 patients for pivotal Phase 3 ZoptEC study
Subscribe for More Information
June 25, 2015
07:37 EDTAEZSAeterna Zentaris selects Ergomed to conduct Phase 3 clinical trial of Macrilen
Aeterna Zentaris announced that it has executed a definitive agreement with Ergomed, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency.
June 18, 2015
07:32 EDTAEZSAeterna Zentaris awarded extension for NASDAQ listing compliance
Aeterna Zentaris has received notice from NASDAQ determining that the company is eligible for an additional 180 calendar day period, until December 14 to regain compliance with the minimum $1.00 per share required for continued listing. The company's shares continue to trade on the NASDAQ Capital Market under the symbol AEZS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use